280 related articles for article (PubMed ID: 20922707)
1. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
García Rodríguez LA; Herings R; Johansson S
Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
[TBL] [Abstract][Full Text] [Related]
2. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
[TBL] [Abstract][Full Text] [Related]
3. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
4. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.
Goettsch WG; Heintjes EM; Kastelein JJ; Rabelink TJ; Johansson S; Herings RM
Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):435-43. PubMed ID: 16761304
[TBL] [Abstract][Full Text] [Related]
5. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.
McAfee AT; Ming EE; Seeger JD; Quinn SG; Ng EW; Danielson JD; Cutone JA; Fox JC; Walker AM
Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):444-53. PubMed ID: 16761308
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
Davidson MH
Expert Opin Drug Saf; 2004 Nov; 3(6):547-57. PubMed ID: 15500414
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme.
Johansson S; Ming EE; Wallander MA; Rodríguez LA; Herings RM; Goettsch WG; González-Pérez A; McAfee AT; Walker AM
Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):454-61. PubMed ID: 16733834
[TBL] [Abstract][Full Text] [Related]
8. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11,680 patients.
Kasliwal R; Wilton LV; Cornelius V; Aurich-Barrera B; Shakir SA
Drug Saf; 2007; 30(2):157-70. PubMed ID: 17253880
[TBL] [Abstract][Full Text] [Related]
11. Liver toxicity of rosuvastatin therapy.
Famularo G; Miele L; Minisola G; Grieco A
World J Gastroenterol; 2007 Feb; 13(8):1286-8. PubMed ID: 17451217
[TBL] [Abstract][Full Text] [Related]
12. Statins and the risk of liver injury: a population-based case-control study.
Chen GL; Hsiao FY; Dong YH; Shen LJ; Wu FL
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):719-25. PubMed ID: 24829162
[TBL] [Abstract][Full Text] [Related]
13. New analysis supports expanded use of statins in women.
Harv Womens Health Watch; 2010 Apr; 17(8):6. PubMed ID: 20506603
[No Abstract] [Full Text] [Related]
14. Rosuvastatin: an independent analysis of risks and benefits.
Zipes DP; Zvaifler NJ; Glassock RJ; Gilman S; Muñoz A; Gogolak V; Gordis L; Dedon PC; Guengerich FP; Wasserman SI; Witztum JL; Wogan GN
MedGenMed; 2006 Jun; 8(2):73. PubMed ID: 16926812
[TBL] [Abstract][Full Text] [Related]
15. Reversible acute hepatitis induced by rosuvastatin.
Oteri A; Catania MA; Russo A; Salvo F; Giacci L; Caputi AP; Polimeni G
South Med J; 2008 Jul; 101(7):768. PubMed ID: 19209117
[No Abstract] [Full Text] [Related]
16. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate.
Ireland JH; Eggert CH; Arendt CJ; Williams AW
Ann Intern Med; 2005 Jun; 142(11):949-50. PubMed ID: 15941707
[No Abstract] [Full Text] [Related]
17. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
[TBL] [Abstract][Full Text] [Related]
18. Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database.
Choi NK; Chang Y; Choi YK; Hahn S; Park BJ
Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):238-46. PubMed ID: 20049851
[TBL] [Abstract][Full Text] [Related]
19. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.
Golightly LK; Barber GR; Barron MA; Page RL
Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530
[TBL] [Abstract][Full Text] [Related]
20. Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program.
Stein EA; Vidt DG; Shepherd J; Cain VA; Anzalone D; Cressman MD
Atherosclerosis; 2012 Apr; 221(2):471-7. PubMed ID: 22304793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
